Lumateperone not checked
Intra-Cellular Therapies, Inc. · ITI-007
FollowEvery change as it happens, and a Monday email
Trials
6 active
23 in total · 3 in the EU
What this is
- How it works
- Atypical Antipsychotic FDA class
- How it’s given
- “Lumateperone 5 mg - 42 mg capsules or orally disintegrating tablets administered orally, once daily based on age and indication”In the company’s words, NCT06229210 on ClinicalTrials.gov
- Tested for
- Irritability Associated With Autism Spectrum Disorder (2 trials), Major Depressive Disorder, Depressive Disorder, Major, Bipolar Depression, Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder
- Main trialPhase 3
- “This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.”In the company’s words, NCT05850689 on ClinicalTrials.gov
- Other names
- Caplyta · ITI-007
Other drugs for Irritability Associated With Autism Spectrum Disorder
- CM-ATCuremark · Phase 3
- NTI164Fenix Innovation Group · Phase 3
- Xanomeline/Trospium ChlorideBristol Myers Squibb · Phase 3
- CodabakalnerSpinogenix · Phase 2/3
- ML-004MapLight Therapeutics · Phase 2
- Terpenes-Enriched CBD-Predominant OilBazelet Nehushtan LtD. · Phase 2
Coming up6
- 5 Apr 2027Phase 3 trial completes · ClinicalTrials.gov
- 21 Jun 2027Phase 3 trial completes · ClinicalTrials.gov
- 21 Jun 2027Phase 3 trial completes · ClinicalTrials.gov
- 20 Sep 2029Phase 3 trial completes · ClinicalTrials.gov
- 31 Oct 2031Phase 3 trial completes · ClinicalTrials.gov
- 28 Apr 2032Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials23
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 5 Apr 2027 | Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | |
| Phase 3Recruiting | 21 Jun 2027 | Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients | |
| Phase 3Recruiting | 21 Jun 2027 | Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients | |
| Phase 3Not yet recruiting | 20 Sep 2029 | A Study of Lumateperone Versus Placebo in Participants With Major Depressive Disorder | |
| Phase 3Recruiting | 31 Oct 2031 | Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients | |
| Phase 3Recruiting | 28 Apr 2032 | Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder | |
| Phase 3Completed | Jul 2015 | A Trial to Assess the Antipsychotic Efficacy of ITI-007 | |
| Phase 3Completed | Aug 2016 | A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment | |
| Phase 3Completed | 28 Jan 2019 | Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression | |
| Phase 3Terminated | 30 Jan 2019 | ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease | |
| Phase 3Completed | 1 Mar 2019 | Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally | |
| Phase 3Completed | 2 Jul 2020 | Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression | |
| Phase 3Completed | 30 Nov 2022 | Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder | |
| Phase 3Completed | 22 Feb 2024 | Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | |
| Phase 3Completed | 12 Apr 2024 | Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | |
| Phase 3Completed | 25 Jul 2024 | Lumateperone for the Prevention of Relapse in Patients With Schizophrenia | |
| Phase 3Completed | 14 Oct 2024 | An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | |
| Phase 3Completed | 24 Feb 2026 | Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania | |
| Phase 3Completed | 15 May 2026 | Study of Lumateperone in the Treatment of Patients With Bipolar Mania | |
| Phase 2Completed | Aug 2013 | Study of a Novel Antipsychotic ITI-007 in Schizophrenia | |
| Phase 1Completed | 30 Jul 2022 | Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder | |
| Phase 1Completed | 20 Nov 2025 | Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder | |
| Phase 1Completed | 26 Nov 2025 | Safety, Tolerability and Pharmacokinetics of Lumateperone in Pediatric Patients With Autism Spectrum Disorder |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026